Published

2020-01-01

Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?

Revisión: Alivia la Gabapentina las Adicciones a Opioides, Cannabis y Metanfetaminas?

Revisão: A Gabapentina Alivia Dependências de Opióide, Cannabis e Metanfetamina?

DOI:

https://doi.org/10.15446/.v29n1.75930

Keywords:

Gabapentin, Cannabis, Methamphetamine, Opioids, Treatment (en)
Gabapentina, Cannabis, Metanfetamina, Opioides, Tratamiento (es)
Gabapentina, Cannabis, Metanfetamina, Opioides, Tratamento (pt)

Downloads

Authors

The study reviews the suitability of using Gabapentin for treating opioid, cannabis and methamphetamine use disorders. This revision consists of 61 biographical references based on a PubMed database search (January of 1983-May of 2018). Gabapentin displayed respectively 50% and 66.7% of success for treating methamphetamine dependence and opioid withdrawal symptoms. Furthermore, a few research studies have reported Gabapentin´s efficacy for alleviating cannabis dependence (two studies), and cannabis withdrawal symptoms (one study). Similarly, a single study reported Gabapentin reduction of opioid consumption during the detoxification process. Based on the revision, we can conclude that: (a) Gabapentin is useful for treating opioid withdrawal symptoms, (b) additional studies are necessary for elucidating the effectiveness of Gabapentin for treating methamphetamine dependence, cannabis dependence and its withdrawal symptoms, and (c) more studies are necessary to confirm the efficacy of Gabapentin in reducing opioid consumption during detoxification.

El trabajo revisa 61 referencias bibliográficas, producto de una búsqueda en la base de datos PubMed (enero de 1983 a mayo de 2018), con el fin de determinar si la Gabapentina es adecuada para el tratamiento de trastornos derivados del uso de opiáceos, cannabis y metanfetaminas. El éxito de la Gabapentina para tratar la dependencia a las metanfetaminas y los síntomas de abstinencia de opiáceos fue de 50% y 66.7%, respectivamente. Algunas investigaciones han informado la eficacia de la Gabapentina para aliviar la dependencia al cannabis (dos estudios) y los síntomas de abstinencia del cannabis (un estudio). Un solo estudio reportó que la Gabapentina redujo el consumo de opiáceos, durante el proceso de desintoxicación. La revisión nos permite concluir que (a) la Gabapentina es útil para tratar los síntomas de abstinencia de los opiáceos, (b) se necesitan más estudios para esclarecer la efectividad de la Gabapentina para tratar la dependencia a las metanfetaminas, al cannabis y los síntomas de abstinencia, y (c) se requieren más estudios para confirmar la eficacia de la Gabapentina para reducir el consumo de opiáceos durante la desintoxicación.

O presente trabalho analisa a eficácia da gabapentina no tratamento de distúrbios de opiáceos, cannabis e metanfetaminas. Esta revisão consiste em 57 referências baseadas em pesquisa no repositório Pub Med (janeiro / 1983 - maio / 2018). A gabapentina mostrou respectivamente 50% e 66,7% de eficácia para tratar a dependência de metanfetaminas e a síndrome de abstinência de opióides. Além disso, há poucos relatos sobre a eficiência da gabapentina em aliviar a dependência (dois estudos) e a síndrome de abstinência (um estudo) à cannabis. Da mesma forma, um estudo relatou que a gabapentina reduz o consumo de opiáceos durante a desintoxicação.  Esta avaliação conclui que: a) a gabapentina é útil para o tratamento da síndrome de abstinência de opióides, b) é necessário mais estudos para determinar se a gabapentina alivia dependência de dependência da metanfetamina e retirada de cannabis, e c) mais estudos são necessários para confirmar se a gabapentina reduz o consumo de opiáceos durante a desintoxicação.

References

Adler, C. H. (1997). Treatment of restless legs syndrome with Gabapentin. Clin Neuropharmacol, 20, 148-151. https://doi.org/10.1097/00002826-199704000-00006

Ahmed, S., Bachu, R., Kotapati, P., Adnan, M., Ahmed, R., Farooq, U., Saeed, H., Khan, A. M. , Zubair, A., Qamar, I., & Begum, G. (2019). Use of Gabapentin in the treatment of substance use and psychiatric disorders: A Systematic Review. Front Psychiatry, 10, 228. https://doi: 10.3389/fpsyt.2019.00228

Arumugam, S., Lau, C. S., & Chamberlain, R. S. (2016). Use of preoperative Gabapentin significantly reduces postoperative opioid consumption: a meta-analysis. J Pain Res, 9, 631-640. https://doi.org/10.2147/jpr. S112626

Balter, R. E., Cooper, Z. D., & Haney, M. (2014). Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep, 1, 137-143. https://doi. org/10.1007/s40429-014-0011-1

Bartoszyk, G. D. & Hamer, M. (1987). The genetic animal model of reflex epilepsy in the Mongolian gerbil: Differential efficacy of new anticonvulsive drugs and prototype antiepileptics. Pharmacol Res Commun, 19, 429-440. https://doi.org/10.1016/0031- 6989(87)90082-8

Bauer C. S., Tran-Van-Minh, A., Kadurin I., & Dolphin, A. C. (2010). A new look at calcium channel α2δ subunits. Current Opinion in Neurobiology, 20, 1-9. https://doi.org/10.1016/j.conb.2010.05.007

Berlin, R. K., Butler, P. M., & Perloff, M. D. (2015). Gabapentin therapy in psychiatric disorders: A systematic review. Prim Care Companion cns Disord, 17. https://doi.org/10.4088/pcc.15r01821

Bockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010). A comparison of the pharmacokinetics and pharmacodynamics of Pregabalin and Gabapentin. Clin Pharmacokinet, 49, 661-669. https://doi.org/10.2165/11536200- 000000000-00000

Brackins, T., Brahm, N. C. & Kissack, J. C. (2011). Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract, 24, 541-550. https://doi.org/10.1177/0897190011426557

Coderre, T. J., Kumar, N., Lefebvre, C. D., & Yu, J. S. (2007). A comparison of the glutamate release inhibition and anti-allodynic effects of Gabapentin, Lamotrigine, and Riluzole in a model of neuropathic pain. J Neurochem, 100, 1289–1299. https://doi. org/10.1111/j.1471-4159.2006.04304.x

Crawford, P., Ghadiali, E., Lane, R., Blumhardt, L., & Chadwick, D. (1987). Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry, 50, 682-686. https://doi.org/10.1136/jnnp.50.6.682

Cunningham, M. O., Woodhall, G. L., Thompson, S. E., Dooley, D. J., & Jones, R. S. (2004). Dual effects of Gabapentin and Pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci, 20, 1566–1576. https://doi.org/10.1111/j.1460- 9568.2004.03625.x

Dickenson, A. H. & Ghandehari, J. (2007). Anti-convulsants and anti-depressants. Handb Exp Pharmacol, 177, 145–177. https://doi.org/10.1007/978-3-540-33823-9_6

Drug Information Portal (April 1, 2018). Search Drug Information Portal. Bethesda, U.S.A: U.S. National Library of Medicine. Recovered from: https://druginfo.nlm.nih.gov/drugportal/name/ gabapentin

Eroglu C., Allen, N. J., Susman, M. W., O’Rourke, N. A., Park, C. Y., Ozkan, E.,…, & Barres, B. A. (2009). Gabapentin receptor a2d-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell, 139, 380-392. https://doi. org/10.1016/j.cell.2009.09.025

Gorelick, D. A. (2016). Pharmacological treatment of cannabis-related disorders: a narrative review. Curr Pharm Des, 22, 6409-6419. https://doi.org/ 10.2174/ 1381612822666160822150822

Hah, J., Mackey, S. C., Schmidt, P., McCue, R., Humphreys, K., Trafton, J.,…, & Carroll, I. (2018). Effect of perioperative Gabapentin on postoperative pain resolution and opioid cessation in a mixed surgical cohort: a randomized clinical trial. jama Surg, 153, 303-311. https://doi.org/10.1001/jamasurg.2017.4915

Heinzerling, K. G., Shoptaw, S., Peck, J. A., Yang, X., Liu, J., Roll, J., & Ling, W. (2006). Randomized, placebocontrolled trial of Baclofen and Gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend, 85, 177-184. https://doi.org/10.1016/j. drugalcdep.2006.03.019

Hengy, H. & Kolle, E. U. (1985). Determination of Gabapentin in plasma and urine by high-performance liquid chromatography and pre-column labelling for ultraviolet detection. J Chromatogr, 341, 473-478. https://doi.org/10.1016/s0378-4347(00)84064-5

Howland, R. H. (2013). Gabapentin for the treatment of substance use disorders. J Psychosoc Nurs Ment Health Serv, 51, 11-14. https://doi.org/10.3928/02793695- 20131120-01

Howland, R. H. (2014). Gabapentin for substance use disorders: is it safe and appropriate? J Psychosoc Nurs Ment Health Serv, 52, 13-16. https://doi. org/10.3928/02793695-20131217-01

Karila, L., Weinstein, A., Aubin, H. J., Benyamina, A., Reynaud, M., & Batki, S. L. (2010). Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol, 69, 578-592. https://doi.org/10.1111/j.1365-2125.2010.03639.x

Kheirabadi, G. R., Ranjkesh, M., Maracy, M. R., & Salehi, M. (2008). Effect of add-on Gabapentin on opioid withdrawal symptoms in opium-dependent patients. Addiction, 103, 1495-1499. https://doi.org/10.1111/j.1360- 0443.2008.02248.x

Kurokawa, K., Shibasaki, M., Mizuno, K., & Ohkuma, S. (2011). Gabapentin blocks methamphetamine-induced sensitization and conditioned place preference via inhibition of alpha(2)/delta-1 subunits of the voltagegated Calcium channels. Neuroscience, 176, 328-335. https://doi.org/10.1016/j.neuroscience.2010.11.062

Landmark, C. J. (2007). Targets for antiepileptic drugs in the synapse. Medical Science Monitor, 13, ra 1–7. Lile, J. A., Wesley, M. J., Kelly, T. H. & Hays, L. R. (2016). Separate and combined effects of gabapentin and Δ9- thc in humans discriminating Δ9-thc. Behavioural Pharmacology, 27, 215-224. https://doi.org/10.1097/ fbp.0000000000000187

Ling, W., Shoptaw, S., Hillhouse, M., Bholat, M. A., Charuvastra, C., Heinzerling, K.,…, & Doraimani, G. (2012). Double-blind placebo-controlled evaluation of the prometa protocol for methamphetamine dependence. Addiction, 107, 361-369. https://doi. org/10.1111/j.1360-0443.2011.03619.x

Mardani-Kivi, M., Karimi Mobarakeh, M., Keyhani, S., Haghighi, M., Hashemi-Motlagh, K., & SahebEkhtiari, K. (2016). Arthroscopic bankart surgery: does Gabapentin reduce postoperative pain and opioid consumption? A triple-blinded randomized clinical trial. Orthop Traumatol Surg Res, 102, 549-553. https://doi.org/10.1016/j.otsr.2016.01.028

Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014). Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev, 12, cd008940. https:// doi.org/ 10.1002/14651858.cd008940.pub2

Martinez-Raga, J., Sabater, A., Perez-Galvez, B., Castellano, M., & Cervera, G. (2004). Add-on Gabapentin in the treatment of opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry, 28, 599-601. https:// doi.org/10.1016/j.pnpbp.2003.11.020

Mason, B. J., Crean, R., Goodell, V., Light, J. M., Quello, S., Shadan, F.,…, & Rao, S. (2012). A proof-ofconcept randomized controlled study of Gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology, 37, 1689-1698. https:// doi.org/10.1038/npp.2012.14

Mellick, G. A. & Mellick, L. B. (1996). Management of restless legs syndrome with Gabapentin (Neurontin). Sleep, 19, 224-226. https://doi.org/10.1093/ sleep/19.3.224

Minozzi, S., Cinquini, M., Amato, L., Davoli, M., Farrell, M. F., Pani, P. P., & Vecchi, S. (1995). Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev, 4,cd006754. https://doi:10.1002/14651858.cd006754. pub4

Moghadam, M. S. & Alavinia, M. (2013). The effects of Gabapentin on methadone based addiction treatment: a randomized controlled trial. Pak J Pharm Sci, 26, 985-989.

National Center for Biotechnology Information (April 1, 2018). Pub Chem Substance Database. Bethesda, U.S.A: U.S. National Library of Medicine. Recovered from: https://pubchem.ncbi. nlm.nih.gov/substance/46506529D

No author listed. (2012). Gabapentin and Pregabalin: abuse and addiction. Prescrire Int, 21, 152-154.

Olive, M. F., Cleva, R. M., Kalivas, P. W., & Malcolm, R. J. (2012). Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav, 100, 801-810. https://doi.org/10.1016/j. pbb.2011.04.015

Quintero, G. C. (2017). Review about Gabapentin misuse, interactions, contraindications and side effects. J Exp Pharmacol, 9, 13-21. https://doi.org/10.2147/jep.s124391

Reimann, W. (1983). Inhibition by gaba, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action? Eur J Pharmacol, 94, 341-344. https://doi. org/10.1016/0014-2999(83)90425-9

Rodriguez-Arias, M., Aguilar, M. A., & Minarro, J. (2015). Therapies in early development for the treatment of opiate addiction. Expert Opin Investig Drugs, 24, 1459-1472. https://doi.org/10.1517/13543 784.2015.1086746

Rogawski, M. A. & Loscher, W. (2004). The neurobiology of antiepileptic drugs. Nat Rev Neurosci, 5, 553–564. https://doi.org/10.1038/nrn1430

Rosner, H., Rubin, L., & Kestenbaum, A. (1996). Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain, 12, 56-58.

Rudolf, G., Walsh, J., Plawman, A., Gianutsos, P., Alto, W., Mancl, L., & Rudolf, V. (2018). A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment. Am J Drug Alcohol Abuse, 44, 302-309. https://doi.org/10.1080/00952990.2017.1334209

Ryback, R. S., Brodsky, L., & Munasifi, F. (1997). Gabapentin in bipolar disorder. J Neuropsychiatry Clin Neurosci, 9, 301. https://doi.org/10.1176/jnp.9.2.301b

Ryback, R. & Ryback, L. (1995). Gabapentin for behavioral dyscontrol. Am J Psychiatry, 152, 1399. https://doi.org/10.1176/ajp.152.9.1399a

Sabioni, P. & Le Foll, B. (2018). Psychosocial and pharmacological interventions for the treatment of cannabis use disorder. F1000Res, 7, 173. https:// doi.org/10.12688/f1000research.11191.1

Salehi, M., Kheirabadi, G. R., Maracy, M. R., & Ranjkesh, M. (2011). Importance of Gabapentin dose in treatment of opioid withdrawal. J Clin Psychopharmacol, 31, 593-596. https://doi.org/10.1097/ jcp.0b013e31822bb378

Sanders, N. C., Mancino, M. J., Gentry, W. B., Guise, J. B., Bickel, W. K., Thostenson, J., & Oliveto, A. H. (2013). Randomized, placebo-controlled pilot trial of Gabapentin during an outpatient, Buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol, 21, 294-302. https://doi. org/10.1037/a0033724

Schlicker, E., Reimann, W. & Gothert, M. (1985). Gabapentin decreases monoamine release without affecting acetylcholine release in the brain. Arzneimittelforschung, 35, 1347-1349.

Segal, A. Z. & Rordorf, G. (1996). Gabapentin as a novel treatment for postherpetic neuralgia. Neurology, 46, 1175-1176. https://doi.org/10.1212/wnl.46.4.1175

Shimoyama, M., Shimoyama, N., Inturrisi, C. E. & Elliott, K. J. (1997). Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test. Pain, 72, 375-382. https://doi. org/10.1016/s0304-3959(97)00065-1

Singh, L., Field, M. J., Ferris, P., Hunter, J. C., Oles, R. J., Williams, R. G., & Woodruff, G. N. (1996). The antiepileptic agent Gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology (Berl), 127, 1-9. https://doi.org/10.1007/bf02805968

Sood, A., Ebbert, J. O., Wyatt, K. D., Croghan, I. T., Schroeder, D. R., Sood, R., & Hays, J. T. (2010). Gabapentin for smoking cessation. Nicotine Tob Res, 12, 300-4. https://doi.org/10.1093/ntr/ntp195

Soyka, M. & Mutschler, J. (2016). Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. Prog Neuropsychopharmacol Biol Psychiatry, 70, 148-161. https://doi.org/10.1016/j. pnpbp.2015.11.003

Urschel, H. C., 3rd, Hanselka, L. L., & Baron, M. (2011). A controlled trial of Flumazenil and Gabapentin for initial treatment of methylamphetamine dependence. J Psychopharmacol, 25, 254-262. https:// doi.org/10.1177/0269881109349837

Urschel, H. C., 3rd, Hanselka, L. L., Gromov, I., White, L., & Baron, M. (2007). Open-label study of a proprietary treatment program targeting type A gamma-aminobutyric acid receptor dysregulation in methamphetamine dependence. Mayo Clin Proc, 82, 1170-1178. https://doi.org/10.4065/82.10.1170

Vollmer, K. O., von Hodenberg, A., & Kolle, E. U. (1986). Pharmacokinetics and metabolism of Gabapentin in rat, dog and man. Arzneimittelforschung, 36, 830-839.

Walden, J. & Hesslinger, B. (1995). Value of old and new anticonvulsants in treatment of psychiatric diseases. Fortschr Neurol Psychiatr, 63, 320-335. https://doi.org/ 10.1055/s-2007-996633

Welty, D. F., Schielke, G. P., & Rothstein, J. D. (1995). Potential treatment of amyotrophic lateral sclerosis with Gabapentin: a hypothesis. Ann Pharmacother, 29, 1164-1167. https://doi. org/10.1177/106002809502901118

Ziaaddini, H., Ziaaddini, A., Asghari, N., Nakhaee, N., & Eslami, M. (2015). Trial of Tramadol plus Gabapentin for opioid detoxification. Iran Red Crescent Med J, 17, e18202. https://doi.org/10.5812/ircmj.18202

Zullino, D. F., Khazaal, Y., Hattenschwiler, J., Borgeat, F. & Besson, J. (2004). Anticonvulsant drugs in the treatment of substance withdrawal. Drugs of Today, 40, 603-619. https://doi.org/10.1358/ dot.2004.40.7.850478

How to Cite

APA

Quintero Garzola, G. C. (2020). Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?. Revista Colombiana de Psicología, 29(1), 143–161. https://doi.org/10.15446/.v29n1.75930

ACM

[1]
Quintero Garzola, G.C. 2020. Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?. Revista Colombiana de Psicología. 29, 1 (Jan. 2020), 143–161. DOI:https://doi.org/10.15446/.v29n1.75930.

ACS

(1)
Quintero Garzola, G. C. Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?. Rev. colomb. psicol. 2020, 29, 143-161.

ABNT

QUINTERO GARZOLA, G. C. Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?. Revista Colombiana de Psicología, [S. l.], v. 29, n. 1, p. 143–161, 2020. DOI: 10.15446/.v29n1.75930. Disponível em: https://revistas.unal.edu.co/index.php/psicologia/article/view/75930. Acesso em: 22 jan. 2025.

Chicago

Quintero Garzola, Gabriel Conrado. 2020. “Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?”. Revista Colombiana De Psicología 29 (1):143-61. https://doi.org/10.15446/.v29n1.75930.

Harvard

Quintero Garzola, G. C. (2020) “Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?”, Revista Colombiana de Psicología, 29(1), pp. 143–161. doi: 10.15446/.v29n1.75930.

IEEE

[1]
G. C. Quintero Garzola, “Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?”, Rev. colomb. psicol., vol. 29, no. 1, pp. 143–161, Jan. 2020.

MLA

Quintero Garzola, G. C. “Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?”. Revista Colombiana de Psicología, vol. 29, no. 1, Jan. 2020, pp. 143-61, doi:10.15446/.v29n1.75930.

Turabian

Quintero Garzola, Gabriel Conrado. “Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?”. Revista Colombiana de Psicología 29, no. 1 (January 1, 2020): 143–161. Accessed January 22, 2025. https://revistas.unal.edu.co/index.php/psicologia/article/view/75930.

Vancouver

1.
Quintero Garzola GC. Review: Does Gabapentin Relieve Opioids, Cannabis and Methamphetamines Addictions?. Rev. colomb. psicol. [Internet]. 2020 Jan. 1 [cited 2025 Jan. 22];29(1):143-61. Available from: https://revistas.unal.edu.co/index.php/psicologia/article/view/75930

Download Citation

CrossRef Cited-by

CrossRef citations0

Dimensions

PlumX

Article abstract page views

1350

Downloads

Download data is not yet available.

License

Copyright (c) 2020 Revista Colombiana de Psicología

The RCP is published under the Creative Commons license and can be copied and reproduced according to the conditions of this license (http://creativecommons.org/licenses/by-nc-nd/2.5). RCP articles are available online at https://revistas.unal.edu.co/index.php/psicologia/issue/archive. If you would like to subscribe to the RCP as reader, please go to https://revistas.unal.edu.co/index.php/psicologia/information/readers and follow the instructions mentioned in the webpage. Additionally, a limited number of print journals are available upon request. To request print copies, please email revpsico_fchbog@unal.edu.co.